Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol

Correction to: Diabetes Ther (2018) 9:37–47 https://doi.org/10.1007/s13300-017-0330-z

In the original publication, the text in Table 2 stated ‘Hypersensitivity to the active substance, to Ferinject, or to any of its excipients’. The authors would like to make changes to the text and have replaced it to ‘Hypersensitivity to ferric carboxymaltose or to any of the excipients of the study medication’. The authors have also made alterations to Fig. 1. Corrected Fig. 1 and Table 2 are given below:

Table 2 Key inclusion and exclusion criteria

Fig. 1

CLEVER study design. ^#Defined as HbA1c ≥ 48 mmol/mol (6.5%) and < 69 mmol/mol (8.5%). ^##Defined as serum ferritin < 150 ng/mL or transferrin saturation < 25% if hemoglobin < 14 g/dL or serum ferritin < 100 ng/mL or transferrin saturation < 20% if hemoglobin ≥ 14 g/dL and ≤ 15 g/dL. *Control parameter: ferritin and transferrin saturation. **If still iron deficient at V2a [serum ferritin < 150 ng/mL or transferrin saturation < 25%], an additional dose of 500 mg ferric carboxymaltose is given at V2b, otherwise it is not